Hepion Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Hepion Pharmaceuticals tiene unos fondos propios totales de $16.2M y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $25.0M y $8.8M respectivamente.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$19.28m |
| Equity | US$16.16m |
| Total liabilities | US$8.84m |
| Total assets | US$25.00m |
Recent financial health updates
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely
Aug 10
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Apr 25We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Oct 27Recent updates
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely
Aug 10We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Apr 25We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Oct 27Hepion Pharma rises as company begins NASH treatment trial
Aug 31Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?
Jul 04Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH
Feb 17Hepion Pharmaceuticals: Facing The Momentous Year 2022
Jan 21Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug
Sep 21Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth
Sep 14Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race
Sep 08Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)
May 26What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?
Feb 18Hepion Pharma cleared to advance final dosing cohort in NASH trial
Dec 29Hepion Pharma to begin CRV431 testing in COVID-19 patients
Dec 22Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study
Dec 10Hepion Pharma prices equity offering at $1.50
Nov 25Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow
Oct 31Financial Position Analysis
Pasivos a corto plazo: HEPALos activos a corto plazo ($21.3M) de la empresa superan a sus pasivos a corto plazo ($6.4M).
Pasivo a largo plazo: HEPALos activos a corto plazo ($21.3M) superan a sus pasivos a largo plazo ($2.4M).
Debt to Equity History and Analysis
Nivel de deuda: HEPA está libre de deudas.
Reducción de la deuda: HEPA no tiene deuda en comparación con hace 5 años, cuando su ratio deuda/fondos propios era de 44.5%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Cash runway estable: HEPA tiene suficiente cash runway para 6 meses según el último flujo de caja libre declarado [flujo de caja libre]], pero desde entonces ha obtenido capital adicional.
Pronóstico de cash runway: HEPA se prevé que disponga de suficiente liquidez para 6 meses según las estimaciones de flujo de caja libre, pero desde entonces ha obtenido capital adicional.